The safety of rosiglitazone in the treatment of Type 2 diabetes

Sonal Singh, Yoon K. Loke

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Background: Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease. Objectives: To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone. Methods: Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers. Conclusion: Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)579-585
Number of pages7
JournalExpert Opinion on Drug Safety
Issue number5
StatePublished - Sep 2008


  • Cardiovascular adverse effects
  • Fractures
  • Heart failure
  • Myocardial infarction
  • Rosiglitazone
  • Safety

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'The safety of rosiglitazone in the treatment of Type 2 diabetes'. Together they form a unique fingerprint.

Cite this